Novo Nordisk (NVO) stock in focus as the company wins FDA accelerated nod for weight loss therapy Wegovy against the liver ...

Novo Nordisk said on Friday the US Food and Drug Administration has granted accelerated approval for its weight-loss drug Wegovy to treat a serious liver ...

While Novo Nordisk say they're fighting against stigma, critics say they could be promoting prescription drugs under the ...

Wegovy® (semaglutide) injection 2.4 mg is now indicated to treat adults with metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver ...

The FDA has granted accelerated approval to Wegovy® (semaglutide) as the first treatment for MASH with moderate-to-advanced ...